Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Core Viewpoint - Clearmind Medicine Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, as its closing bid price has been below $1.00 for the last 30 consecutive business days [1][2]. Compliance Period - The company has been granted a 180-calendar day compliance period until June 2, 2026, to regain compliance with the minimum bid price requirement [2]. - During this compliance period, the company's shares will continue to be listed and traded on Nasdaq under the symbol "CMND" [2]. Regaining Compliance - To regain compliance, the closing bid price must meet or exceed $1.00 per share for at least 10 consecutive business days during the compliance period [2]. - If compliance is not achieved by June 2, 2026, the company may qualify for a second 180-calendar day compliance period, provided it meets other listing requirements [3]. Monitoring and Future Actions - The company intends to monitor its closing bid price and will consider options to resolve the non-compliance issue as necessary [4]. - There is no assurance that the company will regain compliance with the minimum bid price requirement or other Nasdaq listing criteria [4]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, including alcohol use disorder [5]. - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [5].